The company said, “The company today announced financial guidance for 2024. The company anticipates revenue will be in the range of $3 to $5 million, operating expenses will be in the range of $420 to 450 million, and net cash utilization will be approximately $390 to $420 million. Inclusive of approximately $83 million, net, raised in early 2024 through our ATM equity vehicle, our year end cash balance of $655.4 million, plus available long-term debt from Royalty Pharma, represents approximately two years of forward cash based on our projected 2024 operating expenses and net cash utilization.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CYTK:
- Is CYTK a Buy, Before Earnings?
- Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
- Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Cytokinetics weakness a buying opportunity, says Truist
- Cytokinetics CFO Ching W. Jaw Announces Resignation
